HK inno.N Q1 2026: Revenue KRW 258.7B, OP KRW 33.2B, R&D Pipeline Advancing

Q1 2026 results: Revenue KRW 258.7B (+9.3% YoY estimated), operating profit KRW 33.2B (OPM 12.8%), net profit KRW 25.9B
Key product K-CAB: Revenue KRW 45.6B (17.6% of total); US FDA NDA submitted Jan 2026; entered 55 global countries
R&D spending KRW 21.9B (8.5% of sales); Key pipeline: JAK-1 inhibitor (IN-115314) phase 2 in Korea, phase 1 IND in US; GLP-1RA (IN-B00009) phase 3 for obesity/diabetes in Korea; Denosumab biosimilar received domestic marketing approval (Feb 2026)
Financial health: Total assets KRW 2,067.7B, debt ratio 54.6%, net debt ratio 0.45; credit rating A (stable)/A2
Currency sensitivity: 10% KRW change impacts after-tax profit by ~KRW 1.5B; Pending lawsuits (2 cases, KRW 3.4B) considered immaterial